PRN Stock Overview Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Profound Medical Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Profound Medical Historical stock prices Current Share Price CA$10.40 52 Week High CA$15.75 52 Week Low CA$9.55 Beta 0.93 1 Month Change -4.28% 3 Month Change -0.53% 1 Year Change -12.72% 3 Year Change -30.14% 5 Year Change -24.35% Change since IPO -30.70%
Recent News & Updates
Chairman of the Board & CEO recently bought CA$212k worth of stock Dec 12 Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $35.00025 million. Dec 07
Profound Medical Corp. has filed a Follow-on Equity Offering. Dec 06
Profound Medical Corp. Announces Unveiling of Its Third Tulsa-AI Software Module Nov 26
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 09
Profound Medical Corp. Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System Final Rule for CY2025 Nov 05 See more updates
Chairman of the Board & CEO recently bought CA$212k worth of stock Dec 12 Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $35.00025 million. Dec 07
Profound Medical Corp. has filed a Follow-on Equity Offering. Dec 06
Profound Medical Corp. Announces Unveiling of Its Third Tulsa-AI Software Module Nov 26
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 09
Profound Medical Corp. Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System Final Rule for CY2025 Nov 05
Profound Medical Corp. to Report Q3, 2024 Results on Nov 07, 2024 Oct 18
Chairman of the Board & CEO exercised options to buy CA$176k worth of stock. Sep 15
Chairman of the Board & CEO exercised options to buy CA$210k worth of stock. Aug 29
Chief Financial Officer recently bought CA$125k worth of stock Aug 19
New minor risk - Profitability Aug 12
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Profound Medical Corp. to Report Q2, 2024 Results on Aug 08, 2024 Jul 19
Profound Medical Corp. Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases Jul 12
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan May 15
New minor risk - Profitability May 12
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024 May 12
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024 May 11
First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.32 loss in 1Q 2023) May 10
Forecast to breakeven in 2026 May 10
Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet? May 03
Profound Medical Corp. to Report Q1, 2024 Results on May 09, 2024 Apr 23
Chief Commercial Officer of US recently sold CA$95k worth of stock Mar 29
Chief Commercial Officer of US notifies of intention to sell stock Mar 28
Profound Medical Corp., Annual General Meeting, May 15, 2024 Mar 12
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 10
New major risk - Revenue and earnings growth Mar 09
Profound Medical Corp. to Report Q4, 2023 Results on Mar 07, 2024 Feb 16 Profound Medical Corp. announced that it expects to receive $2.937503 million in funding Jan 17
Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million. Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million. Profound Medical Corp. Announces CMD Extension of Temporary Code for TULSA to ASC Setting
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 03
Profound Medical Corp. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost Sep 26
Is Profound Medical (TSE:PRN) Using Debt In A Risky Way? Sep 15
New minor risk - Shareholder dilution Sep 10
Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint Aug 10
Profound Medical Corp. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
New minor risk - Shareholder dilution Jul 07
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases Jun 03
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 08
Profound Medical Corp. to Report Q4, 2022 Results on Mar 07, 2023 Feb 15
Chairman & CEO recently bought CA$138k worth of stock Dec 23
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 05
Profound Medical Corp. to Report Q3, 2022 Results on Nov 03, 2022 Oct 14
Profound Medical Corp. Announces Updated Results from the TACT (TULSA-PRO® Ablation Clinical Trial) Sep 27
Profound Medical Corp. Announces Changes to Commercial Organization to Support Continued Growth Sep 16
Will Profound Medical (TSE:PRN) Spend Its Cash Wisely? Sep 07
Profound Medical Corp. Provides TULSA-PRO Reimbursement Update Sep 03
Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.35 loss in 2Q 2021) Aug 05
Profound Medical Corp. to Report Q2, 2022 Results on Aug 04, 2022 Jul 15
Independent Director recently bought CA$123k worth of stock Jun 04
Profound Medical Corp. Elects Kris Shah to Board of Director May 19
Profound Medical Corp. Unveils TULSA-PRO Software Release 2.11, Which Includes Two New Features May 18
Independent Lead Director recently bought CA$459k worth of stock May 14
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 10
Insufficient new directors Apr 27
Profound Medical Corp. to Report Q1, 2022 Results on May 09, 2022 Apr 19
Chairman & CEO recently bought CA$637k worth of stock Mar 12
Forecast to breakeven in 2024 Mar 06
No longer forecast to breakeven Mar 04
Profound Medical Corp. Confirms the TULSA-PRO Systems New Compatibility with GE Healthcares 3T Mar 03
Profound Medical Corp. to Report Q4, 2021 Results on Mar 03, 2022 Feb 11
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the Tulsa Procedure to Radical Prostatectomy Jan 19
Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation Jan 07
Forecast to breakeven in 2024 Jan 02
Chairman & CEO recently bought CA$125k worth of stock Nov 12
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10
Chairman & CEO exercised options to buy CA$634k worth of stock. Sep 04
Independent Director recently bought CA$127k worth of stock Aug 19
Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.33 loss in 2Q 2020) Aug 09 Shareholder Returns PRN CA Medical Equipment CA Market 7D -2.7% -8.8% -4.1% 1Y -12.7% -11.7% 16.7%
See full shareholder returns
Return vs Market: PRN underperformed the Canadian Market which returned 16.7% over the past year.
Price Volatility Is PRN's price volatile compared to industry and market? PRN volatility PRN Average Weekly Movement 6.4% Medical Equipment Industry Average Movement 13.9% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.8% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: PRN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: PRN's weekly volatility (6%) has been stable over the past year.
About the Company Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Show more Profound Medical Corp. Fundamentals Summary How do Profound Medical's earnings and revenue compare to its market cap? PRN fundamental statistics Market cap CA$251.80m Earnings (TTM ) -CA$45.18m Revenue (TTM ) CA$12.93m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PRN income statement (TTM ) Revenue US$8.98m Cost of Revenue US$3.41m Gross Profit US$5.57m Other Expenses US$36.96m Earnings -US$31.39m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.27 Gross Margin 62.02% Net Profit Margin -349.41% Debt/Equity Ratio 18.0%
How did PRN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 00:19 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Profound Medical Corp. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Kideckel Beacon Securities Limited Jason Mills Canaccord Genuity Prakash Gowd CIBC Capital Markets
Show 12 more analysts 
